|Bid||23.07 x 0|
|Ask||23.08 x 0|
|Day's range||22.96 - 23.60|
|52-week range||22.03 - 48.88|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||42.72|
|Earnings date||22 Apr 2022 - 25 Apr 2022|
|Forward dividend & yield||0.23 (0.99%)|
|Ex-dividend date||31 May 2022|
|1y target est||45.36|
Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is CNY 18.12 per share, representing a market cap of CNY 10.419 billion.
Qiming Venture Partners announced today the closing of its latest funds totaling US$3.2 billion, including USD Fund VIII at US$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million).
SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a Master Collaboration Agreement (Agreement) with AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company. The master collaboration agreement enables the Parties to collaborate in the development and commercialization of AmoyDx assays that may cover any type of indication